Key Inclusions

• An executive summary of the key insights captured during our research, offering a high-level view on the current state of the non-viral drug delivery systems market and its likely evolution in the short to mid and long term.
• A brief introduction to important concepts related to non-viral intracellular drug delivery, featuring information on various types of non-viral drug delivery systems and their primary applications in the healthcare domain, along with details related to the recent advancements that have been reported in this market space.
• A detailed review of the overall market landscape of non-viral drug delivery systems, featuring an in-depth analysis based on several relevant parameters, such as therapeutic portfolio, type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, DNA, RNA and proteins / peptides), type of interaction (co-administration, conjugation, encapsulation and others) and Type of Technology (cell penetrating peptides, extracellular vesicles, oligonucleotides, nanoparticles, polymers). In addition, it features a list of technology developers and a detailed analysis based on their year of establishment, company size, type of company and geographical location.
• An in-depth analysis, highlighting the contemporary market trends, using four schematic representations, including a waffle chart representation, (highlighting the distribution of various types of vehicles used for delivering payloads), a heat map representation (based on company size and type of molecule delivered), a vertical stacked column bar chart representation (location of headquarters and type of service provider), a vertical column clustered chart representation (based on company size and location of headquarters).
• An insightful company competitiveness analysis of non-viral drug delivery systems providers, taking into consideration various relevant parameters, such as years of experience and product portfolio (in terms of number of technologies offered, type of biologics delivered and type of linkage) and partnership strength (in terms of number of partnerships, partnership year, partnerships based on geographies, type of partnerships, therapeutic area, payment portfolio and type of biologics delivered).
• Elaborate profiles of prominent players engaged in offering non-viral drug delivery technologies, across North America, Europe and Asia. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details on its technology portfolio and recent developments and an informed future outlook.
• An in-depth analysis of the various patents that have been filed / granted patent related to intracellular drug delivery technologies, based on various parameters, such as type of patent, publication year, application year, granted patents, filed patents, issuing authority, type of player, CPC symbols (in terms of the size of intellectual property portfolio), leading industry / non-industry players and inventors (in terms of number of patents filed / granted). Further it features a patent benchmarking analysis and a detailed patent valuation analysis.

• An insightful analysis of various partnerships inked between stakeholders engaged within the non-viral drug delivery domain, based on several relevant parameters, such as year of partnership, type of partner (industry and non-industry), purpose of partnership (research and development, research, development and commercialization, product development, product development and commercialization, product development and manufacturing, product development and manufacturing, commercialization, manufacturing, acquisition / merger and others), type of partnership (technology licensing agreements, technology evaluation agreements, technology integration agreements, technology utilization agreements, acquisitions / mergers and others), therapeutic area (oncological disorders, infectious diseases, genetic disorders, hepatic disorders, neurological disorders, cardiovascular disorders, ophthalmic diseases, pulmonary diseases, metabolic disorders, immunological disorders and others), type of payment model (upfront payments, milestone payments, royalties and others), type of molecule delivered (small molecules, biologics), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
• An insightful framework which provides four zones of evaluation and product portfolio matrix based on various parameters, such as number of drugs in the pipeline, number of companies, deal amount, partnership activity, trends highlighted in number of grants, number of publications, google hits and qualitative scoring. It also provides a Kalbach, competitive assessment framework and BCG matrix for respective non-viral drug delivery technologies currently employed by stakeholders.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

• Type of Molecule
• Small Molecule
• Biologic

• Type of Biologic
• Antibodies
• DNA
• RNA
• Proteins / Peptides

• Type of Technologies
• Cell Penetrating Peptides
• Extracellular Vesicles
• Oligonucleotides
• Nanoparticles
• Polymers

• Target Therapeutic Area
• Infectious Diseases
• Oncological Disorders
• Genetic Disorders
• Neurological Disorders
• Hepatic Disorders
• Cardiovascular Disorders
• Other Disorders

• Type Of Payment Model
• Upfront Payments
• Milestone Payments

• Key Geographical Regions 
• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa (MENA)
• Rest of the world 

Key Questions Answered

• Who are the leading players engaged in the development of intracellular drug delivery technologies?
• Which partnership models are commonly adopted by stakeholders engaged in this domain?
• What type of molecules can be delivered using intracellular drug delivery technologies?
• How is the intellectual property landscape related to intracellular drug delivery likely to evolve in the foreseen future?
• How is the current and future market opportunity likely to be distributed across key market segments and geographical regions?

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html

You may also be interested in the following titles:

You may also like to learn what our experts are sharing in Roots educational series:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com